• Advance Multidisciplinary Care in Lung Cancer: Make use of evidence-based strategies across surgery, radiation, medical oncology, pathology, radiology, nursing, and supportive care to optimize outcomes for patients with lung cancer.
• Evaluate Innovations in Screening, Early Detection, and Risk Reduction: Assess advances in lung cancer screening programs, novel imaging, and the role of prevention strategies—including tobacco control and occupational risk mitigation—to reduce disease burden.
• Implement Personalized Treatment Approaches: Apply current evidence on molecular testing, biomarker-driven therapies, and targeted treatments—including ADCs, TKIs, and immunotherapies—to tailor interventions for diverse patient populations.
• Explore the Evolving Landscape of Immunotherapy: Critically evaluate emerging data on immune checkpoint inhibitors, combination strategies, bispecifics, and their management in special populations such as patients with autoimmune diseases, transplants, or brain metastases.
• Enhance Management of Early and Locally Advanced Disease: Discuss best practices and evolving approaches for resectable and unresectable NSCLC, including neoadjuvant, adjuvant, and perioperative strategies, as well as advanced radiotherapy and ablative techniques.
• Address Challenges in SCLC, NENs, and Rare Thoracic Tumors: Examine new diagnostic, molecular, and therapeutic developments in small cell lung cancer, neuroendocrine tumors, mesothelioma, and thymic malignancies to improve patient care.
• Integrate Novel Diagnostic and Monitoring Tools: Evaluate the utility of advanced imaging, multiomic analyses, liquid biopsies (including ctDNA and methylation), and digital pathology in staging, treatment response, and surveillance.
• Improve Care Delivery in Resource-Limited and Diverse Settings: Identify barriers and implement solutions for equitable access to molecular testing, precision oncology, and advanced therapies in low- and middle-income countries and underserved populations.
• Promote Shared Decision-Making and Patient-Centered Care: Model approaches to communication, survivorship planning, and addressing quality of life, emphasizing patient preferences, advocacy, and integrative care.
• Foster Interactive Learning and Collaborative Problem-Solving: Apply new knowledge to complex clinical scenarios and enhance decision-making in lung cancer care by engaging in case-based discussions, polling, and multidisciplinary debates.

The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational planning process to ensure independence, balance, objectivity and scientific rigor for all Continuing Medical Education (CME) activities.  

In compliance with the ACCME Standards, each individual in a position to control the content of a CME activity is required to disclose all financial relationships with ACCME defined ineligible companies. All disclosures are reviewed to identify relevant financial relationships, and any conflicts of interest are mitigated before the individual can assume their role in the activity.  

All disclosures can be found HERE and will also be available on the Conference app. 

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of the IASLC or any company that provided commercial support for this activity. 

The IASLC 2025 World Conference on Lung Cancer (WCLC 2025) is the world’s largest international conference for clinicians, researchers and scientists in the field of lung cancer and thoracic oncology. Bringing together lung cancer specialists from around the world and across disciplines, the conference offers opportunities for learning and sharing the latest developments in lung cancer and thoracic malignancy research, prevention, diagnosis, treatment and management. With 20 educational tracks and over 300 global experts as invited speakers, WCLC 2025 provides a robust, comprehensive scientific program encompassing cutting edge knowledge on subjects such as tumor biomarkers, clinical trials, targeted therapies, liquid biopsy, lung cancer screening, immunotherapy, tobacco control and patient advocacy. Sessions include plenaries with live Q&A, expert lectures, panel discussions, oral abstracts and posters.

The IASLC 2025 World Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants.

The below list includes countries that accept ACCME-accredited continuing medical education (CME). Please note that some countries that accept ACCME-accredited education do not have specific credit requirements for their physicians. For additional information: https://accme.org/about-accreditation/countries-accepting-accme-accredited-cme/

Antigua & Barbuda
REGULATOR
Antigua & Barbuda Medical Council

Austria
REGULATOR
Austrian Academy of Physicians on behalf of the Austrian Medical Chamber

Bahamas
REGULATOR
Bahamas Medical Council

Belgium
REGULATOR
Group of Belgian Professional Unions of Specialist Doctors

Bhutan
REGULATOR
Medical and Health Professional Council, Royal Government of Bhutan

Croatia
REGULATOR
Croatian Medical Chamber

Gambia, The
REGULATOR
The Medical and Dental Council of the Gambia

Germany
REGULATOR
State Chambers of Physicians in the 16 federal states
(only in-person, live events)

India, State of Punjab
REGULATOR
Punjab Medical Council

Israel
REGULATOR
Scientific Council, Israeli Medical Association

Jamaica
REGULATOR
Medical Council of Jamaica

Kuwait
REGULATOR
Professional Licensing - Ministry of Health

Malawi
REGULATOR
Medical Council of Malawi

Netherlands, The
REGULATOR
Royal Dutch Society of the Promotion of Medicine

Oman
REGULATOR
Oman Medical Specialty Board

Qatar
REGULATOR
Accreditation Section of the Department of Healthcare Professions of the Qatar Ministry of Public Health

Rwanda
REGULATOR
Rwanda Medical & Dental Council

Saudi Arabia
REGULATOR
Saudi Commission for Health Specialties

Singapore
REGULATOR
Singapore Medical Council

South Africa
REGULATOR
Health Professions Council of South Africa

Spain
REGULATOR
Spanish Medical Professional Accreditation Council for CPD/CME

Sri Lanka
REGULATOR
Sri Lanka Medical Council, Sri Lanka Medical Association, and the Ministry of Health

Sweden
REGULATOR
Swedish Medical Association

Tunisia
REGULATOR
INEAS (Instance Nationale de l'Evaluation et de l'Accréditation en santé)

Trinidad & Tobago
REGULATOR
The Trinidad and Tobago Medical Association

Turkey
REGULATOR
Turkish Medical Association CME-CPD Accreditation Council

United Arab Emirates, Abu Dhabi
REGULATOR
Department of Health

United Arab Emirates, Dubai
REGULATOR
Dubai Health Authority

The official language of the IASLC 2025 World Conference on Lung Cancer is English.